Effect on quality of life of advanced sarcoma patients after anti-angiogenesis therapies of apatinib
YANG Chen-chen
DONG Sen
XU Jie
XIE Lu
YANG Yi
JI Tao
GUO Wei
TANG Xiao-dong
Abstract：Objective We analyzed files about quality of life(QoL)and adverse effects(AEs)from two clinical trials of apatinib for advanced sarcoma(NCT02711007 and NCT03491371).Methods Dynamic QoL scores in three major domains were analyzed by t-test.The effect of these ese AEs on general health score(GHS)was then analyzed using linear regression models to find out which was the most important factor affecting QoL.Results QoL has a slight end of decline after anti-angiogenic therapy,however,with no statistical significance(P=0.154).Pneumothorax(14.6%),wound dehiscence(11.0%),appetite loss(6.1%)and hypertension(6.1%)were the most common grade 3/4 AEs.The appearance of pneumothorax was closely related to a lower GHS(P=0.002).Conclusions QoL for advanced sarcoma patients has a non-significant trend of decline after anti-angiogenic therapy.Pneumothorax,as the most common grade 3/4 AEs,is the major concern related to poor general quality of life,resulting in poor function and aggravated symptoms.
Keywords：Angiogenesis inhibitorsSarcomaDrug-related side effects and adverse reactionsQuality of lifeApatinib
Publication Date：2024-05-19
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 365-371 )